LOGIN  |  REGISTER
Chimerix

DexCom (NASDAQ: DXCM) Stock Quote

Last Trade: US$116.12 0.05 0.04
Volume: 1,277,241
5-Day Change: -0.92%
YTD Change: -6.42%
Market Cap: US$46.180B

Latest News From DexCom

Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. ADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s. 1,2 New Dexcom G7 automated insulin delivery integrations * further solidify the company’s undisputed leadership in CGM connectivity. Recently released Dexcom G7... Read More
HealthStocksHub
Diabetes management goes hands-free as Dexcom G7 now connects directly to Apple Watch * in the U.S., giving users confidence even when their iPhone isn’t with them † As the first and only CGM system that connects directly to Apple Watch, * Dexcom G7 gives users the freedom and convenience of real-time glucose readings on their... Read More
HealthStocksHub
Nova Scotia becomes the latest province and territory to offer access to simple and easy-to-use diabetes management solutions, helping Canadians living with diabetes take control of their health BURNABY, British Columbia / Jun 03, 2024 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous... Read More
SAN DIEGO / May 29, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5 th . The live presentation is scheduled to begin at approximately 4:20 PM EST and will be concurrently webcast. Links to the webcast will be available... Read More
SAN DIEGO / Apr 25, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic 1 basis. U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an... Read More
Report advances Dexcom’s corporate sustainability disclosures, including expanded greenhouse gas emissions data and greater transparency in pay-equity practices SAN DIEGO / Apr 03, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability... Read More
SAN DIEGO / Apr 02, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor worn on the back of the upper arm, Stelo will provide glucose insights directly to a user’s smartphone † Created by the makers of Dexcom G7, the most accurate, 1 easy-to-use 2 and clinically-proven CGM brand, 3-7 Stelo will... Read More
SAN DIEGO / Feb 27, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5 th . The live presentation is scheduled to begin at approximately 8:40 AM EST and will be concurrently webcast. Links to the webcast will be... Read More
SAN DIEGO / Feb 08, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic 1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported... Read More
SAN DIEGO / Jan 23, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently... Read More
The company also announced Stelo, its new glucose sensor for people with type 2 diabetes who do not use insulin, has been submitted to the U.S. Food and Drug Administration for review and is expected to launch in the U.S. in summer 2024 SAN DIEGO / Jan 08, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited... Read More
SAN DIEGO / Dec 19, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42 nd annual J.P. Morgan Healthcare Conference on January 8, 2024. The live presentation is scheduled to begin at approximately 12:45 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom... Read More
HealthStocksHub
With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when... Read More
SAN DIEGO / Nov 21, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35 th Annual Healthcare Conference on Wednesday, November 29 th . The live presentation is scheduled to begin at approximately 8:30 AM EST and will be concurrently webcast. Links to the webcast will be... Read More
HealthStocksHub
Dexcom is helping the world #SeeDiabetes with a first-of-its-kind portrait gallery featuring the faces of people with diabetes from all walks of life and from all corners of the world, including celebrities Nick Jonas, Patti LaBelle and Jeremy Irvine. The #SeeDiabetes campaign and portrait gallery supports Dexcom’s ongoing... Read More
SAN DIEGO / Oct 26, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $975.0 million on a reported basis and 26% on an organic 1 basis. U.S. revenue growth of 24% and international revenue growth of 33% on a reported basis.... Read More
HealthStocksHub
Dexcom G7 is available for people with all types of diabetes ages two years and older, giving more Canadians than ever access to a simple, accurate 1 and effective diabetes management solution BURNABY, British Columbia / Oct 05, 2023 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose... Read More
COMISAIR study is now the longest prospective real-world CGM study ever conducted, demonstrating significant and continued HbA1c reduction for patients using real-time CGM over seven years. 1 New data shows the Dexcom ONE CGM system delivers a clinically meaningful increase in time in range, reduction in HbA1c and improved glucose control for users with Type 2 diabetes. 2 Based on a recent study of 96 pregnant women... Read More
SAN DIEGO / Sep 29, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management will hold a conference call to review the company's third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More
HealthStocksHub
The partnership will pair cutting-edge technology from Dexcom with daily food tracking to provide a more comprehensive and personalized care experience for those living with diabetes BURNABY, British Columbia / Sep 21, 2023 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose... Read More
HealthStocksHub
In its second season, the 2023 Dexcom U roster consists of 20 athletes with diabetes across 10 sports, 20 colleges, and includes 11 new team members Expanded program gives these collegiate athletes a platform to share their stories, serve as role models and inspire other people with diabetes SAN DIEGO / Sep 19, 2023 / Business... Read More
SAN DIEGO / Aug 30, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023 at 3:45pm (EDT). Sean Christensen, Vice President,... Read More
SAN DIEGO / Aug 28, 2023 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023. Ms. Driscoll is an accomplished leader with significant experience developing, guiding and executing organic and inorganic growth strategies for global organizations. She currently serves as... Read More
BURNABY, British Columbia / Aug 15, 2023 / Business Wire / Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to Work ® in Canada for 2023-24. Awarded by Great Place to Work Institute ® , the global authority on workplace culture, this certification is based on direct feedback from... Read More
SAN DIEGO / Jul 27, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights: Revenue grew 25% versus the same quarter of the prior year to $871.3 million on a reported basis and 26% on an organic 1 basis. U.S. revenue growth of 21% and international revenue growth of 38% on a reported basis. International... Read More
SAN DIEGO / Jul 06, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call to review the company's second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More
HealthStocksHub
Dexcom G7 is the most accurate CGM system 1 approved by Health Canada, building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hypoglycemia, and improve time in range 2,3,4 . Made with users in mind, Dexcom G7 combines simplicity and power, introducing a better way to manage diabetes... Read More
New Dexcom product with 15-day wear, a cash-pay option and a tailored software experience for people who don’t use insulin is expected to launch in the U.S. in 2024 Access and availability of Dexcom CGM is expanding globally, with Dexcom G7 now available in 14 countries and the recent launch of Dexcom ONE in Argentina marking the company’s first entrance into Latin America Private payers in the U.S. are following Medicare’s... Read More
SAN DIEGO / Jun 23, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced an update to its long-range financial targets at its 2023 Investor Day. Based on the company’s strong performance in the first two years of the target period, Dexcom is updating its year-end 2025 financial targets to the following levels: 2025 Revenue of approximately $4.6 - $5.1 billion (previously $4.0 - $4.5 billion) 2025 Non-GAAP Gross... Read More
SAN DIEGO / Jun 08, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23 rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations from Dexcom management highlighting the company’s market opportunities, business strategy, innovation efforts, and long-term financial outlook. Links to a live webcast of the event will... Read More
SAN DIEGO / Jun 01, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7 th . The live presentation is scheduled to begin at approximately 1:40 PM EST and will be concurrently webcast. Links to the webcast will be available on... Read More
SAN DIEGO / May 03, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate... Read More
SAN DIEGO / May 02, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the... Read More
SAN DIEGO / Apr 27, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights: Revenue grew 18% versus the same quarter of the prior year to $741.5 million on a reported basis and 19% on an organic 1 basis. U.S. revenue growth of 17% and international revenue growth of 21% on a reported basis. International... Read More
HealthStocksHub
The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and Inuit peoples for improved diabetes management BURNABY, British Columbia / Apr 27, 2023 / Business Wire / Dexcom, Inc. (NASDAQ:... Read More
HealthStocksHub
Medicare patients using all types of insulin now have coverage for Dexcom G7 * – giving approximately 1.5 million more Americans access to the most accurate, 1 simple to use 1 CGM at the same cost as other CGM brands † Dexcom-backed MOBILE study was the primary piece of clinical evidence that led to the expansion of coverage 2... Read More
SAN DIEGO / Apr 06, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will hold a conference call to review the company's first quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More
Report advances Dexcom’s environmental, social, and governance (ESG) transparency by providing new disclosures, including company’s first greenhouse gas emissions inventory and enhanced human capital reporting SAN DIEGO / Apr 05, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report, which... Read More
BURNABY, British Columbia / Mar 21, 2023 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced that its Dexcom G6 CGM System will be available to people of all ages with type 1 and type 2 diabetes in Manitoba who meet eligibility criteria. Expanding coverage for rtCGM to include all eligible patients with type 1 or type 2 diabetes... Read More
SAN DIEGO / Mar 13, 2023 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article: “Dexcom does not have material exposure to the developments at Silicon Valley Bank, including with respect to the company’s cash deposits. Although the company has worked successfully with SVB for many years,... Read More
SAN DIEGO / Feb 23, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: Sean Christensen, Vice President, Finance and Investor Relations, will present on behalf of the company at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 2:45pm (EST). Jereme Sylvain,... Read More
SAN DIEGO / Feb 13, 2023 / Business Wire / Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries. † Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all... Read More
SAN DIEGO / Feb 09, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights: Revenue grew 17% versus the same quarter of the prior year to $815.2 million on a reported basis and 20% on an organic 1 basis. U.S. revenue growth of 17% and international revenue growth of 15% on a reported... Read More
SAN DIEGO / Feb 07, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second Super Bowl commercial , which announces the US launch of its next-generation Dexcom G7 CGM System. The ad, which will run during the second quarter of Super Bowl LVII on Feb. 12, 2023, stars multi-platinum recording artist,... Read More
SAN DIEGO / Jan 24, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a conference call to review the company's fourth quarter and full year 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently... Read More
HealthStocksHub
Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program. Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits... Read More
DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be at least $815 million, an increase of 17% over the fourth quarter of 2021 on a reported basis and 20% on an organic 1 basis. U.S. revenue is expected to be approximately $606 million, representing growth of 17% over the... Read More
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief commercial officer. In this role, Ms. Lawver will oversee the global commercial organization with responsibility for global sales, marketing and customer experience. Ms. Lawver comes to Dexcom with extensive healthcare and global... Read More
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41 st annual J.P. Morgan Healthcare Conference on January 9, 2023. The live presentation is scheduled to begin at approximately 2:15 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB